Incara Compound Results to Be Presented at 14th International Symposium On ALS/MND
18 Novembre 2003 - 2:15PM
PR Newswire (US)
Incara Compound Results to Be Presented at 14th International
Symposium On ALS/MND RESEARCH TRIANGLE PARK, N.C., Nov. 18
/PRNewswire-FirstCall/ -- Incara Pharmaceuticals Corporation
(BULLETIN BOARD: INCR) announced that animal results for its
catalytic antioxidant compound, AEOL 10150, in development for
treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's
disease) will be presented at the 14th International Symposium on
ALS/MND (motor neuron disease) in Milan, Italy. John P. Crow,
Ph.D., Professor of Pharmacology and Toxicology at the University
of Arkansas College of Medicine, will make the presentation at the
joint closing session of the conference on Wednesday afternoon,
November 19. In recent experiments conducted by Dr. Crow in a
transgenic mouse model of ALS, the survival time period after
symptom onset for the AEOL 10150-treated group of mice was over 2.5
times the survival period of the control group. Data from these
experiments can be viewed at Incara's website
http://www.incara.com/ . "Dr. Crows preclinical findings encourage
us to move AEOL 10150 forward as a treatment for ALS," stated
Clayton I. Duncan, Chairman and CEO of Incara. "Not only is the
animal data impressive, it is robust. Since he first presented his
results in September, Dr. Crow has repeated the experiment, which
has now been conducted four times with similar results, including
most recently using the same route of administration planned for
clinical trials." ALS, the most common motor neuron disease,
results from progressive degeneration of both upper and lower motor
neurons and is usually fatal within 5 years. Assuming satisfactory
completion of animal safety studies, and completion of the
remaining components of its recently announced financing, Incara
intends to file an IND application for the treatment of ALS in the
second quarter of 2004. Allowance of the IND by the FDA would
permit Incara to initiate clinical trials. The clinical program
will test the ability of AEOL 10150 treatment to extend the
survival of ALS patients. Incara has been granted orphan drug
designation by the FDA for AEOL 10150 for the treatment of ALS.
Incara Pharmaceuticals Corporation is developing a new class of
small molecule catalytic antioxidants that destroy oxygen-derived
free radicals, believed to be an important contributor to the
pathogenesis of many diseases. Incara's catalytic antioxidants have
been shown to reduce damage to tissue in animal studies of
neurological disorders such as amyotrophic lateral sclerosis (Lou
Gehrig's disease) and stroke, and in other non-neurological
indications such as cancer radiation therapy, chronic bronchitis
and asthma. The statements in this press release that are not
purely statements of historical fact are forward-looking
statements, and actual results might differ materially from those
anticipated. These statements and other statements made elsewhere
by Incara or its representatives, which are identified or qualified
by words such as "intends," "likely," "will," "suggests,"
"expects," "might," "may," "believe," "could," "should," "would,"
"anticipates," "plans," or the negative of those terms or similar
expressions, are based on a number of assumptions that are subject
to risks and uncertainties. Important factors that could cause
results to differ include risks associated with the uncertainties
of clinical trials, product development activities and scientific
research and the need to conserve and obtain funds for operations.
These and other important risks are described in Incara's reports
on Form 10-K, Form 10-Q and Form 8-K and its registration
statements filed with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Incara assumes no obligation to update the information in this
release. DATASOURCE: Incara Pharmaceuticals Corporation CONTACT: W.
Bennett Love of Incara Pharmaceuticals Corporation, +1-919-558-1907
Web site: http://www.incara.com/
Copyright